Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 9/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115073 | 0.88 | TUBB3 (0.50) | DHFRPDGFRBEGFRTUBB3KDR | |
| SCHEMBL3114838 | 0.81 | TUBB3 (0.47) | DHFRPDGFRBEGFRTUBB3KDR | |
| Trifluoroacetic Acid SCHEMBL3126704 | 0.79 | TUBB3 (0.45) | DHFRPDGFRBEGFRTUBB3KDR | |
| SCHEMBL3126711 | 0.78 | TUBB3 (0.45) | DHFRPDGFRBEGFRTUBB3KDR | |
| SCHEMBL3122059 | 0.78 | TUBB3 (0.49) | DHFRPDGFRBEGFRTUBB3KDR | |
| SCHEMBL3112443 | 0.78 | TUBB3 (0.49) | DHFRPDGFRBEGFRTUBB3KDR | |
| SCHEMBL3120807 | 0.78 | TUBB3 (0.49) | DHFRPDGFRBEGFRTUBB3KDR | |
| SCHEMBL3118924 | 0.78 | ABCB1 (0.47) | DHFRPDGFRBEGFRTUBB3KDR | |
| SCHEMBL3107648 | 0.77 | TUBB3 (0.48) | DHFRPDGFRBEGFRTUBB3KDR | |
| SCHEMBL3113432 | 0.76 | ABCB1 (0.47) | DHFRPDGFRBEGFRTUBB3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | claimed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100068197-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | DHFR 426/4885PDGFRB 2783/4885EGFR 3147/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | DHFR 482/4885PDGFRB 2627/4885EGFR 2648/4885 |
| US-20100068197-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MKI67, CCNI, CCNA1 | DHFR 173/4885PDGFRB 625/4885EGFR 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.